Increased adenosine production due to upregulation of CD38 by tumor cells was identified as another mechanism of resistance to PD-1 and PD-L1 checkpoint blockade, and inhibition of CD38 was shown to significantly improve responses to an anti-PD-L1 antibody [86]. This evidence concerns the gene CD38 and neoplasm.